The use of 225Ac in prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT), either as monotherapy or in combination with 177Lu, is a promising therapy approach in patients with metastatic castration-resistant prostate carcinoma (mCRPC). In this study, we report the efficacy and safety of [225Ac]Ac-PSMA-617 augmented [177Lu]Lu-PSMA-617 RLT in 177Lu-naive mCRPC patients (n = 15) with poor prognosis (presence of visceral metastases, high total tumor burden with diffuse bone metastases or a short PSA doubling time of <2 months). Biochemical (by PSA serum value) and molecular imaging response (by [68Ga]Ga-PSMA-11 PET/CT) was assessed after two cycles of [177Lu]Lu-PSMA-617 RLT, with at least one [225Ac]Ac-PSMA-617 aug...
Background: Prostate-specific membrane antigen (PSMA)-directed radioligand therapy (RLT) is a novel ...
Lu-177-labeled PSMA-617 is a promising new therapeutic agent for radioligand therapy (RLT) of patien...
Lu-177-labeled PSMA-617 is a promising new therapeutic agent for radioligand therapy (RLT) of patien...
Prostate-specific membrane antigen radioligand therapy (PSMA-RLT) with 177Lu-PSMA holds great prom...
Purpose Preliminary data from retrospective analyses and recent data from large randomized controlle...
Prostate cancer can be targeted by ligands to the prostate-specific membrane antigen (PSMA). We aime...
Background: Prostate-specific membrane antigen (PSMA)-directed radioligand therapy (RLT) is a novel...
Rationale: Despite the promising results of prostate-specific membrane antigen (PSMA)-targeted 177Lu...
BACKGROUND : A remarkable therapeutic efficacy has been demonstrated with 225Ac-prostate-specific me...
Background: A remarkable therapeutic efficacy has been demonstrated with 225Ac-prostate-specific mem...
Lu-177-labeled PSMA-617 is a promising new therapeutic agent for radioligand therapy (RLT) of patien...
177Lu-PSMA is a new, promising treatment option in patients with metastatic castration-resistent pro...
For patients with metastatic castration-resistant prostate cancer (mCRPC), the survival benefit of c...
The treatment of metastatic castration resistant prostate cancer is still a major medical challenge....
Despite the approval of several new agents metastatic castration resistant prostate cancer is still ...
Background: Prostate-specific membrane antigen (PSMA)-directed radioligand therapy (RLT) is a novel ...
Lu-177-labeled PSMA-617 is a promising new therapeutic agent for radioligand therapy (RLT) of patien...
Lu-177-labeled PSMA-617 is a promising new therapeutic agent for radioligand therapy (RLT) of patien...
Prostate-specific membrane antigen radioligand therapy (PSMA-RLT) with 177Lu-PSMA holds great prom...
Purpose Preliminary data from retrospective analyses and recent data from large randomized controlle...
Prostate cancer can be targeted by ligands to the prostate-specific membrane antigen (PSMA). We aime...
Background: Prostate-specific membrane antigen (PSMA)-directed radioligand therapy (RLT) is a novel...
Rationale: Despite the promising results of prostate-specific membrane antigen (PSMA)-targeted 177Lu...
BACKGROUND : A remarkable therapeutic efficacy has been demonstrated with 225Ac-prostate-specific me...
Background: A remarkable therapeutic efficacy has been demonstrated with 225Ac-prostate-specific mem...
Lu-177-labeled PSMA-617 is a promising new therapeutic agent for radioligand therapy (RLT) of patien...
177Lu-PSMA is a new, promising treatment option in patients with metastatic castration-resistent pro...
For patients with metastatic castration-resistant prostate cancer (mCRPC), the survival benefit of c...
The treatment of metastatic castration resistant prostate cancer is still a major medical challenge....
Despite the approval of several new agents metastatic castration resistant prostate cancer is still ...
Background: Prostate-specific membrane antigen (PSMA)-directed radioligand therapy (RLT) is a novel ...
Lu-177-labeled PSMA-617 is a promising new therapeutic agent for radioligand therapy (RLT) of patien...
Lu-177-labeled PSMA-617 is a promising new therapeutic agent for radioligand therapy (RLT) of patien...